AMGN

Business Context and Reporting Period

Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Its core commercial products include EPOGEN (anemia), NEUPOGEN (neutropenia), INFERGEN (hepatitis C), and STEMGEN (stem cell transplantation). The company operates manufacturing facilities in the U.S., Puerto Rico, and the Netherlands, with a global sales force.

Key Financial Metrics (Year Ended Dec 31, 2000)

Liquidity: Total cash, cash equivalents, and marketable securities stood at $2,028.1 million. The company maintains a $200 million commercial paper program and a $150 million credit facility.

Material Changes vs. Prior Period

• Product Sales Growth: Total product sales increased 5% to $3.2 billion. EPOGEN sales rose 12% ($1.96 billion) driven by U.S. dialysis patient population growth, though partially offset by inventory drawdowns. NEUPOGEN sales declined 3% ($1.22 billion) due to wholesaler buying patterns and foreign exchange headwinds. INFERGEN sales dropped 45% ($14.5 million) due to competition.
• Corporate Partner Revenues: Increased 53% to $246.2 million, primarily due to development fees from Kirin-Amgen for ARANESP (darbepoetin alfa).
• Expenses: R&D expenses rose 3% to $845.0 million. SG&A expenses increased 26% to $826.9 million due to staff costs and marketing for new product launches.
• Non-Recurring Items: "Other items, net" included a $73.9 million legal award from a Johnson & Johnson arbitration, offset by a $30.1 million write-off of in-process R&D from the Kinetix acquisition and a $25.0 million charitable contribution.

Guidance, Outlook, and Risks

2001 Outlook

• Sales Growth: Total product sales expected to grow in the mid-to-high teens. Combined EPOGEN and ARANESP sales expected to grow high teens to low twenties. NEUPOGEN sales growth expected in the high single digits.
• Expenses: R&D and SG&A estimated at 25-27% of total product sales. Cost of sales expected at 11.5-12.5% of product sales.
• Earnings: EPS expected to grow in the mid-teens. Effective tax rate expected to be approximately 34%.

Key Risks and Contingencies

• Regulatory & Reimbursement: Sales depend heavily on government reimbursement (Medicare/Medicaid) and private payors. Changes in rates or policies could materially impact revenue.
• Product Development: High uncertainty in clinical trials. Recent failures include BDNF (ALS) and native leptin (obesity).
• Legal Proceedings: Ongoing patent litigation with Transkaryotic Therapies/Aventis regarding erythropoietin patents (Amgen won summary judgment in Jan 2001, but appeals are pending). Litigation with Biogen and Genentech regarding NEUPOGEN and INFERGEN patents.
• Competition: Intense competition in anemia, cancer, and inflammation markets from large pharmaceutical firms and biotech startups.

Investor Verification Checklist

• ARANESP Approval: Verify the timing of FDA and EU regulatory approvals for ARANESP (darbepoetin alfa), as this is critical for the 2001 sales guidance.
• Reimbursement Policy: Monitor HCFA (now CMS) reimbursement rates for EPOGEN under the ESRD Program, as this is the primary revenue driver.
• Patent Litigation Status: Track the outcome of appeals in the Transkaryotic Therapies/Aventis case and the Biogen/Genentech cases, as adverse rulings could threaten core product exclusivity.
• NEUPOGEN Demand: Assess the impact of less myelosuppressive chemotherapy regimens on NEUPOGEN demand.
• Stock Repurchases: Verify execution of the new $2 billion stock repurchase program authorized in December 2000.